Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 46% vs 12%. @RheumNow #ACR22 Abstr#0533 https://t.co/7kpeXWjeKI https://t.co/Sx41DOJAAX

• Sputum RA-Associated Autoantibodies Independently Associate with Future Develop…

Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reactive arthritis, 0.75 sero-RA, 0.5 PsA. Promising but not there yet. @RheumNow #ACR22 Abstr#0531 https://t.co/clLR0V33WJ https://t.co/7Hts9gtkW9

• Development and Performance of a Diagnostic Precision Biomarker for Seronegativ…

Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database. Residual pain and harm minimisation still areas of need. @RheumNow #ACR22 ABST0925 https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY

• Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheu…

Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

What has changed since the 2020 @ACRheum #reproductive guidelines? Abstract #1717 425 SLE/RA patients: 📍 significant improvement in pre-#pregnancy counseling and discussions in reproductive goals 📍No improvements in birth control use or documentation